The radiopharmaceuticals market was valued at $5.2 billion in 2022, and is estimated to reach $13.7 billion by 2032, growing at a CAGR of 10.2% from 2023 to 2032. Radiopharmaceutical is defined as the radioactive drugs which are used to monitor, diagnose and treat a wide range of disease. The radiopharmaceuticals are widely used for therapeutic and diagnostic purposes. In therapeutic application, the radiopharmaceuticals are administered in some amount so that the proper therapeutic dose of radiation are delivered to specific disease sites. Meanwhile, in diagnostic procedures, the body is exposed to a small amount of radiation in order to observe the function of the organ. The radioactive drugs possess short half-lives; hence they must reach the patient for administration immediately after they manufacture.
The radiopharmaceuticals market is driven by the rise in prevalence of target disease such as cancer, neurological disease and cardiovascular disease, and increase in use of radiopharmaceutical in medical imaging. According to the World Cancer Research Fund International, in 2020, it was reported that around 18.1 million new cancer cases are diagnosed, globally. Radiopharmaceuticals use the radioactive substances to diagnose and treat cancer. Some of the radiopharmaceuticals that are used in diagnosis of cancer are Axumin, PYLARIFY, CERIANNA, Locametz, and Lymphoseek. In addition, the researchers also aims to develops novel radiopharmaceuticals agents, which is designed to deliver the radiation therapy specifically and directly to cancel cells. The surge in the demand for radiation therapy, and rise in number of diagnosis procedure for cancer and other target disease thus propel the growth of the market.
Furthermore, the radiopharmaceutical is used during the positron emission tomography (PET) imaging, in order to assist the examination of biological tissue. The increase in number of prostate, cardiac and amyloid imaging, surge the need for PET procedure. Increase in demand for medical imaging, surge the need for radiopharmaceuticals and boosts the growth of the radiopharmaceuticals market.Increase in the number of product approvals for radiopharmaceuticals fuels the growth of the market.
For instance, in March 2023, Telix Pharmaceuticals, a biotechnology company, announced the U.S Food and Drug Administration (FDA), approval for Illuccix. It is radiolabel with Ga 68 to form a radioactive diagnostic agent. It is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In addition, in March 2022, the U.S Food and Drug Administration (FDA), announced the approval of Pluvicto, for the treatment of adult patient with prostate cancer. Pluvicto, is the first PSMA-targeted radiopharmaceutical, contain lutetium Lu 177 vipivotide tetraxetan, radioisotopes.
In addition, increase in R&D activities in healthcare industry, propel the growth of the market. The Institute for Nuclear Sciences Applied to Health at the University of Coimbra, actively involved in the R&D activities to meet the present and future demand for application of diagnostic radiopharmaceuticals. Moreover, increase in the number of clinical trials on radiopharmaceuticals boosts the growth of the radiopharmaceuticals market. Furthermore, rise in investment for R&D activities in healthcare further boosts market growth. However, factors that hinder the market growth include side effect associated with the use of radiopharmaceutical such as nausea, vomiting, abdominal pain, and back pain.
On the other hand, the presence of radiopharmaceutical industry, increase in R&D activities for radiopharmaceuticals and growth potential in emerging markets are expected to create immense opportunities for radiopharmaceuticals during the forecast period.
The radiopharmaceuticals market is segmented on the basis of radioisotopes, application, type, end user and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. The others include Indium-111, Yttrium-90, Lutetium Lu-177, Copper-64, Carbon-14, Carbon-11, Strontium-89, Rubidium-82, Radium-223, Nitrogen-13, Molybdenum, Gallium-67, Thallium-201, and Xenon-133. On the basis of application, the market is bifurcated into cancer, cardiology and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutics. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. The others segment include diagnostic centers, and research institute.
On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and Rest of LAMEA).Major key players that operate in the global radiopharmaceuticals market are Cardinal Health Inc., Curium Pharma, Eli Lilly and Company, General Electric Company, Iso-Tex Diagnostics, Inc., Jubilant Pharmova Limited, Lantheus Holdings, Inc., Novartis AG, Siemens AG, and Bayer.
The radiopharmaceuticals market is driven by the rise in prevalence of target disease such as cancer, neurological disease and cardiovascular disease, and increase in use of radiopharmaceutical in medical imaging. According to the World Cancer Research Fund International, in 2020, it was reported that around 18.1 million new cancer cases are diagnosed, globally. Radiopharmaceuticals use the radioactive substances to diagnose and treat cancer. Some of the radiopharmaceuticals that are used in diagnosis of cancer are Axumin, PYLARIFY, CERIANNA, Locametz, and Lymphoseek. In addition, the researchers also aims to develops novel radiopharmaceuticals agents, which is designed to deliver the radiation therapy specifically and directly to cancel cells. The surge in the demand for radiation therapy, and rise in number of diagnosis procedure for cancer and other target disease thus propel the growth of the market.
Furthermore, the radiopharmaceutical is used during the positron emission tomography (PET) imaging, in order to assist the examination of biological tissue. The increase in number of prostate, cardiac and amyloid imaging, surge the need for PET procedure. Increase in demand for medical imaging, surge the need for radiopharmaceuticals and boosts the growth of the radiopharmaceuticals market.Increase in the number of product approvals for radiopharmaceuticals fuels the growth of the market.
For instance, in March 2023, Telix Pharmaceuticals, a biotechnology company, announced the U.S Food and Drug Administration (FDA), approval for Illuccix. It is radiolabel with Ga 68 to form a radioactive diagnostic agent. It is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In addition, in March 2022, the U.S Food and Drug Administration (FDA), announced the approval of Pluvicto, for the treatment of adult patient with prostate cancer. Pluvicto, is the first PSMA-targeted radiopharmaceutical, contain lutetium Lu 177 vipivotide tetraxetan, radioisotopes.
In addition, increase in R&D activities in healthcare industry, propel the growth of the market. The Institute for Nuclear Sciences Applied to Health at the University of Coimbra, actively involved in the R&D activities to meet the present and future demand for application of diagnostic radiopharmaceuticals. Moreover, increase in the number of clinical trials on radiopharmaceuticals boosts the growth of the radiopharmaceuticals market. Furthermore, rise in investment for R&D activities in healthcare further boosts market growth. However, factors that hinder the market growth include side effect associated with the use of radiopharmaceutical such as nausea, vomiting, abdominal pain, and back pain.
On the other hand, the presence of radiopharmaceutical industry, increase in R&D activities for radiopharmaceuticals and growth potential in emerging markets are expected to create immense opportunities for radiopharmaceuticals during the forecast period.
The radiopharmaceuticals market is segmented on the basis of radioisotopes, application, type, end user and region. On the basis of radioisotopes, the market is classified into Technetium-99m, Fluorine-18, Iodine I, Gallium-68, and others. The others include Indium-111, Yttrium-90, Lutetium Lu-177, Copper-64, Carbon-14, Carbon-11, Strontium-89, Rubidium-82, Radium-223, Nitrogen-13, Molybdenum, Gallium-67, Thallium-201, and Xenon-133. On the basis of application, the market is bifurcated into cancer, cardiology and others. On the basis of type, the market is bifurcated into diagnostic, and therapeutics. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. The others segment include diagnostic centers, and research institute.
On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and Rest of LAMEA).Major key players that operate in the global radiopharmaceuticals market are Cardinal Health Inc., Curium Pharma, Eli Lilly and Company, General Electric Company, Iso-Tex Diagnostics, Inc., Jubilant Pharmova Limited, Lantheus Holdings, Inc., Novartis AG, Siemens AG, and Bayer.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2022 to 2032 to identify the prevailing radiopharmaceuticals market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Iodine I
- Gallium 68
- Others
- Technetium 99m
- Fluorine 18
By Application
- Cancer
- Cardiology
- Others
By Type
- Diagnostic
- Therapeutic
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Cardinal Health Inc.
- Curium Pharma
- Eli Lilly and Company
- General Electric Company
- Iso-Tex Diagnostics, Inc
- Jubilant Pharmova Limited
- Lantheus Holdings, Inc.
- Novartis AG
- Siemens AG
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY TYPE
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY END USER
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Bayer AG
- Cardinal Health Inc.
- Curium Pharma
- Eli Lilly and Company
- General Electric Company
- Iso-Tex Diagnostics, Inc
- Jubilant Pharmova Limited
- Lantheus Holdings, Inc.
- Novartis AG
- Siemens AG
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
